New mRNA vaccine shows promise against pancreatic cancer, may extend life by 10 years
SMRTR summary
A personalized mRNA vaccine for pancreatic cancer has shown promise in a small phase 1 trial, potentially extending patient survival by up to 10 years. Half of the 16 participants with operable tumors responded positively, producing long-lasting T cells that could target cancer cells for decades, offering hope for improved treatment of this deadly disease.
SMRTR provides this summary for quick context. The original article belongs to Interesting Engineering.
Read the original article